Investment Analysts’ updated eps estimates for Thursday, April 10th:
Addus HomeCare (NASDAQ:ADUS) had its market outperform rating reaffirmed by analysts at JMP Securities. They currently have a $150.00 price target on the stock.
AES (NYSE:AES) had its hold rating reiterated by analysts at Jefferies Financial Group Inc.. They currently have a $10.00 target price on the stock, down from their previous target price of $15.00.
Anixa Biosciences (NASDAQ:ANIX) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $10.00 target price on the stock.
Aptiv (NYSE:APTV) had its neutral rating reaffirmed by analysts at UBS Group AG. They currently have a $58.00 price target on the stock, down from their previous price target of $91.00.
Arcturus Therapeutics (NASDAQ:ARCT) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $60.00 price target on the stock.
Andrada Mining (LON:ATM) had its buy rating reaffirmed by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 11 ($0.14) target price on the stock.
Autolus Therapeutics (NASDAQ:AUTL) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $10.00 target price on the stock.
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $15.00 price target on the stock.
Brookdale Senior Living (NYSE:BKD) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $8.00 target price on the stock.
BorgWarner (NYSE:BWA) had its neutral rating reissued by analysts at UBS Group AG. They currently have a $31.00 target price on the stock, down from their previous target price of $38.00.
Cboe Global Markets (NASDAQ:CBOE) had its neutral rating reaffirmed by analysts at Bank of America Co.. The firm currently has a $227.00 target price on the stock, down from their previous target price of $260.00.
Cidara Therapeutics (NASDAQ:CDTX) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $35.00 price target on the stock.
Charter Communications (NASDAQ:CHTR) had its underperform rating reaffirmed by analysts at BNP Paribas. BNP Paribas currently has a $290.00 target price on the stock.
Costco Wholesale (NASDAQ:COST) had its outperform rating reissued by analysts at Telsey Advisory Group. They currently have a $1,100.00 target price on the stock.
Cryoport (NASDAQ:CYRX) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $11.00 target price on the stock.
Cytokinetics (NASDAQ:CYTK) had its market outperform rating reiterated by analysts at JMP Securities. They currently have a $78.00 price target on the stock.
Docebo (NASDAQ:DCBO) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $42.00 price target on the stock.
Easterly Government Properties (NYSE:DEA) had its neutral rating reiterated by analysts at Compass Point. They currently have a $9.50 price target on the stock, down from their previous price target of $15.00.
Devolver Digital (LON:DEVO) had its hold rating reiterated by analysts at Shore Capital.
Evolus (NASDAQ:EOLS) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $27.00 price target on the stock.
Eversource Energy (NYSE:ES) had its underweight rating reissued by analysts at JPMorgan Chase & Co.. The firm currently has a $58.00 target price on the stock, down from their previous target price of $69.00.
Endeavour Silver (NYSE:EXK) (TSE:EDR) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $7.25 target price on the stock.
Ford Motor (NYSE:F) had its neutral rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They currently have a $9.00 target price on the stock, down from their previous target price of $11.00.
First Advantage (NYSE:FA) had its equal weight rating reiterated by analysts at Barclays PLC. They currently have a $15.00 target price on the stock, down from their previous target price of $20.00.
Franklin Covey (NYSE:FC) had its outperform rating reaffirmed by analysts at Barrington Research. They currently have a $35.00 price target on the stock.
Fortrea (NASDAQ:FTRE) had its underweight rating reaffirmed by analysts at Barclays PLC. Barclays PLC currently has a $6.00 target price on the stock, down from their previous target price of $12.00.
Generation Bio (NASDAQ:GBIO) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $8.00 target price on the stock.
General Motors (NYSE:GM) (TSE:GMM.U) had its neutral rating reissued by analysts at UBS Group AG. UBS Group AG currently has a $51.00 price target on the stock, down from their previous price target of $64.00.
Alphabet (NASDAQ:GOOGL) had its market perform rating reissued by analysts at JMP Securities.
hVIVO (LON:HVO) had its buy rating reaffirmed by analysts at Shore Capital.
ICON Public (NASDAQ:ICLR) had its equal weight rating reaffirmed by analysts at Barclays PLC. They currently have a $165.00 target price on the stock, down from their previous target price of $240.00.
IMAX (NYSE:IMAX) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $30.00 target price on the stock.
IMAX (NYSE:IMAX) had its buy rating reissued by analysts at Rosenblatt Securities. The firm currently has a $35.00 target price on the stock.
Immunocore (NASDAQ:IMCR) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $71.00 target price on the stock.
Immuneering (NASDAQ:IMRX) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $12.00 target price on the stock.
Immunic (NASDAQ:IMUX) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $17.00 target price on the stock.
Inozyme Pharma (NASDAQ:INZY) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $16.00 target price on the stock.
IQVIA (NYSE:IQV) had its equal weight rating reissued by analysts at Barclays PLC. They currently have a $170.00 target price on the stock, down from their previous target price of $235.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $210.00 price target on the stock.
JD Sports Fashion (LON:JD) had its buy rating reiterated by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 128 ($1.64) price target on the stock.
JD Sports Fashion (LON:JD) had its buy rating reiterated by analysts at Shore Capital.
Lear (NYSE:LEA) had its neutral rating reissued by analysts at The Goldman Sachs Group, Inc.. They currently have a $84.00 target price on the stock, down from their previous target price of $117.00.
Littelfuse (NASDAQ:LFUS) had its hold rating reaffirmed by analysts at Benchmark Co..
Lineage (NASDAQ:LINE) had its sector perform rating reiterated by analysts at Scotiabank. They currently have a $56.00 price target on the stock, down from their previous price target of $74.00.
Liquidia (NASDAQ:LQDA) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $25.00 target price on the stock.
Manhattan Associates (NASDAQ:MANH) had its hold rating reaffirmed by analysts at Loop Capital. Loop Capital currently has a $170.00 target price on the stock, down from their previous target price of $275.00.
Masimo (NASDAQ:MASI) had its hold rating reiterated by analysts at Needham & Company LLC.
Microbot Medical (NASDAQ:MBOT) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $9.00 target price on the stock.
MBX Biosciences (NYSE:MBX) had its buy rating reissued by analysts at Guggenheim. Guggenheim currently has a $44.00 price target on the stock.
Marks Electrical Group (LON:MRK) had its buy rating reiterated by analysts at Shore Capital.
Nasdaq (NASDAQ:NDAQ) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $95.00 target price on the stock.
Neumora Therapeutics (NASDAQ:NMRA) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $5.00 target price on the stock.
Norcros (LON:NXR) had its buy rating reissued by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 350 ($4.47) price target on the stock.
Norcros (LON:NXR) had its buy rating reaffirmed by analysts at Shore Capital.
Beigene (NASDAQ:ONC) had its buy rating reiterated by analysts at Guggenheim. They currently have a $348.00 price target on the stock.
Pacific Biosciences of California (NASDAQ:PACB) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. The firm currently has a $3.00 target price on the stock.
Paragon Banking Group (LON:PAG) had its buy rating reaffirmed by analysts at Shore Capital.
PHINIA (NYSE:PHIN) had its neutral rating reissued by analysts at UBS Group AG. They currently have a $45.00 target price on the stock, down from their previous target price of $56.00.
Primary Health Properties (LON:PHP) had its buy rating reissued by analysts at Shore Capital.
Portland General Electric (NYSE:POR) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $44.00 target price on the stock, down from their previous target price of $50.00.
Primoris Services (NASDAQ:PRIM) had its buy rating reissued by analysts at Guggenheim. The firm currently has a $110.00 price target on the stock.
Privia Health Group (NASDAQ:PRVA) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $30.00 price target on the stock.
Personalis (NASDAQ:PSNL) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $7.00 price target on the stock.
Protagonist Therapeutics (NASDAQ:PTGX) had its buy rating reissued by analysts at HC Wainwright. They currently have a $80.00 target price on the stock.
AVITA Medical (NASDAQ:RCEL) had its buy rating reissued by analysts at D. Boral Capital. They currently have a $22.00 target price on the stock.
Remitly Global (NASDAQ:RELY) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $32.00 target price on the stock.
The Rank Group (LON:RNK) had its buy rating reaffirmed by analysts at Shore Capital.
Seven Hills Realty Trust (NASDAQ:SEVN) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $14.50 price target on the stock.
STERIS (NYSE:STE) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $265.00 price target on the stock.
Constellation Brands (NYSE:STZ) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $215.00 target price on the stock.
TruBridge (NASDAQ:TBRG) had its equal weight rating reissued by analysts at Stephens. Stephens currently has a $28.00 price target on the stock.
Tempus AI (NASDAQ:TEM) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $70.00 target price on the stock.
Thryv (NASDAQ:THRY) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $28.00 price target on the stock.
Tharisa (LON:THS) had its buy rating reaffirmed by analysts at Berenberg Bank. They currently have a GBX 130 ($1.66) target price on the stock.
Tempest Therapeutics (NASDAQ:TPST) had its sector perform rating reiterated by analysts at Scotiabank. They currently have a $9.00 target price on the stock, up from their previous target price of $7.00.
Tempest Therapeutics (NASDAQ:TPST) had its neutral rating reissued by analysts at HC Wainwright. They currently have a $16.00 price target on the stock.
Tesco (LON:TSCO) had its buy rating reiterated by analysts at Shore Capital.
Taysha Gene Therapies (NASDAQ:TSHA) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $6.00 price target on the stock.
Visteon (NASDAQ:VC) had its neutral rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. The Goldman Sachs Group, Inc. currently has a $74.00 target price on the stock, down from their previous target price of $103.00.
Visteon (NASDAQ:VC) had its neutral rating reissued by analysts at UBS Group AG. They currently have a $76.00 target price on the stock, down from their previous target price of $114.00.
Wendy’s (NASDAQ:WEN) had its equal weight rating reissued by analysts at Stephens. The firm currently has a $15.00 target price on the stock.
Walmart (NYSE:WMT) had its outperform rating reissued by analysts at Telsey Advisory Group. They currently have a $115.00 target price on the stock.
Receive News & Ratings for Addus HomeCare Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare Co and related companies with MarketBeat.com's FREE daily email newsletter.
